Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Alzheimer’s Disease – Unmet Need – Unmet Need – Early Alzheimer’s Disease (US/EU)

Login to access report north_east
Contact sales account_box

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-related safety risks. Emerging DMTs with near-term launch potential (e.g., subcutaneous lecanemab, Eli Lilly’s remternetug, Roche’s trontinemab, Novo Nordisk’s semaglutide) may deliver greater biomarker and/or clinical efficacy, lower ARIA risk, or improved delivery profiles. This report examines the influence of a key clinical (e.g., reduction of cognitive and functional decline, plaque clearance, ARIA risk) and nonclinical (i.e., out-of-pocket cost) attributes on neurologists’ prescribing decisions and assesses the key opportunities for differentiation from Leqembi, Kisunla, and procognitive symptomatics in the early AD market.

QUESTIONS ANSWERED

  • How important is a therapy’s effect on cognition, function, or biomarker outcomes in neurologists’ selection of a therapy for early AD?
  • How do neurologists rate Leqembi, Kisunla, and procognitive symptomatics on their overall performance in the treatment of early AD and on key individual attributes?
  • Based on conjoint analysis and TPP simulation, what trade-offs among efficacy, safety, treatment duration, and other factors are neurologists willing to make when considering a hypothetical DMT for early AD?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

  • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
  • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
  • Analyze market scenarios for different target product profiles using the TPP Simulator

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 32 European neurologists fielded in December 2023

Key companies: AbbVie, Biogen, Eisai, Eli Lilly, Roche

Key drugs: Leqembi, Kisunla, donepezil, galantamine, Namzaric, rivastigmine patch

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east